Armata (ARMP) traded down -5.22 % during a 24 hours period ending at 10:06 PM Central Europe on Tuesday 27th. One Armata stock can currently be bought for about USD 3.49 on popular exchanges. Current supply of Armata stocks is 37.1 mn. Armata has a current market capitalization of USD 135.3 mn and approximately USD 219.4 k worth of Armata was traded on exchanges in the last 24 hours. Since last month end, Armata has traded -8.73 % down. Simple moving average of last 200 days is at USD 7.08. The highest price of past 52 weeks was recorded at USD 14.98 on 04/22/2026. 52 weeks low was at USD 2.75 on 10/14/2026.

Here is how related stocks have performed in the past 24 hours:

  • Amaero (AMRO) traded down -8.05 % and now trades at USD 6.04. Current market capitalisation for Amaero is USD 161.9 mn. Amaero Inc. has announced that it will publish its third‑quarter 2026 financial results after market close on Monday, November 9, 2026. The company will host a conference call and webcast that same day to discuss the performance of the period ending September 30, 2026. Moving its reporting to U.S. generally accepted accounting principles, Amaero will continue to provide results on a fiscal year ending December 31. The announcement reiterates the firm’s role as a producer of high‑value refractory and titanium alloy powders for additive manufacturing and as a pioneer in powder metallurgy hot isostatic pressing for large near‑net‑shape components, highlighting its strategic importance to U.S. national security and industrial resilience.

  • Westwood (WHG) traded down -0.27 % and now trades at USD 18.94. Westwood has a market capitalisation of USD 161.6 mn. Current price/earnings ratio for Westwood is 21.81.

  • Neuronetics (STIM) traded up 6.16 % and now trades at USD 2.19. Neuronetics has a market capitalisation of USD 162.2 mn.

  • Brc (RILYP) traded up 5.32 % and now trades at USD 8.1. Current market capitalisation for Brc is USD 162 mn. Current price/earnings ratio for Brc is 0.49. BRC Group, a provider of financial analytics, noted that the recent decline in several technology‑focused stocks has prompted a reassessment among analysts. While market sentiment around AI‑related equities has weakened, a significant majority of experts still recommend purchases, citing potential upside in the sector. Analysts highlight that the performance of companies such as Alphabet, Broadcom, Core Scientific, Micron Technology, and Vistra remains supported by underlying growth drivers, including cloud expansion, chip demand, and infrastructure needs. The group’s commentary underlines that the perceived price corrections may be overstated and that a sustained rebound is plausible if the broader AI investment momentum continues.

  • Perspective Therapeutics (CATX) traded down -24.84 % and now trades at USD 1.19. Current market capitalisation for Perspective Therapeutics is USD 161 mn.

About Armata

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Marina Del Rey, United States. The company’s mission is to improve human health by developing novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. By focusing on these areas, Armata Pharmaceuticals serves patients in California and aims to make a significant impact in the health care sector.